C12 Di-Sulfo Galactosyl(β) Ceramide (d18:1/12:0) (ammonium salt)
| Catalog Number | BL-M001132 |
| CAS Number | 852043-40-4 |
| Description | C12 Di-Sulfo Galactosyl(β) Ceramide (d18:1/12:0) (ammonium salt) has been identified as a promising pharmaceutical compound for addressing neurological ailments associated with lipid dysregulation. Preliminary investigations have showcased its efficacy in ameliorating debilitating conditions including Alzheimer's disease and multiple sclerosis, heralding a potential breakthrough in therapeutic interventions. |
| IUPAC Name | diazanium;[(2R,5S)-2-[(E,2S,3R)-2-(dodecanoylamino)-3-hydroxyoctadec-4-enoxy]-3,5-dihydroxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate |
| Synonyms | 3,6-di-O-sulfo-D-galactosyl-β1-1'-N-lauroyl-D-erythro-sphingosine (ammonium salt); 3,6-Sulfo-C12 GalCer (ammonium salt); 3,6-di-O-sulfo-β-D-C12-galactosylceramide (ammonium salt) |
| Molecular Weight | 838.12 |
| Molecular Formula | C36H75N2O14S2 |
| Purity | >99% |
| Appearance | Powder |
| Shelf Life | 1 Year |
| Storage | Store at -20°C |
| Percent Composition | C 51.59%, H 9.02%, N 5.01%, O 26.73%, S 7.65% |
| Canonical SMILES | CCCCCCCCCCCCCC=CC(C(COC1C(C(C(C(O1)COS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NC(=O)CCCCCCCCCCC)O.[NH4+].[NH4+] |
| InChI | InChI=1S/C36H69NO14S2.2H3N/c1-3-5-7-9-11-13-14-15-16-18-19-21-23-25-30(38)29(37-32(39)26-24-22-20-17-12-10-8-6-4-2)27-48-36-34(41)35(51-53(45,46)47)33(40)31(50-36)28-49-52(42,43)44;;/h23,25,29-31,33-36,38,40-41H,3-22,24,26-28H2,1-2H3,(H,37,39)(H,42,43,44)(H,45,46,47);2*1H3/b25-23+;;/t29-,30+,31?,33-,34?,35?,36+;;/m0../s1 |
| InChI Key | GGRFFZCYGYNFLG-GDJXUAKWSA-N |
※ Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Related Products
Online Inquiry
